Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …

Tumor necrosis factor-α inhibitors (TNFis) have revolutionized the management of
rheumatoid arthritis (RA), however despite considerable progress, only a small proportion of …

Anti-drug antibodies (ADAbs) develop in up to a third of patients treated with biologic agents,
with such immunogenicity being one of the main reasons for the loss of efficacy observed in …

Objectives A systematic review was conducted to explore the immunogenicity of biologic
agents across inflammatory diseases and its potential impact on efficacy/safety. Methods …

Up to 40% of patients treated with tumor necrosis factor alpha inhibitors (TNFi) do not
respond to therapy. Testing drug bioavailability and/or anti-drug antibody (ADAb) levels may …

Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of
rheumatic diseases since their incorporation into treatment protocols two decades ago …

Introduction: Genetically engineered monoclonal antibodies and fusion proteins directed
against cytokines or their receptors represent a breakthrough in the treatment of various …

Biologic therapies, predominantly TNF-α inhibitors, have revolutionized the treatment of
rheumatoid arthritis (RA). However, their clinical utility can be limited by the development of …

The introduction of biologics, especially tumour necrosis factor (TNF) inhibitors, has
revolutionized the management of chronic inflammatory diseases. However, at least one …

We examined the assay formats used to detect anti-drug antibodies (ADA) in clinical studies
of the anti-tumour necrosis factor (TNF) monoclonal antibodies adalimumab and infliximab …